Example: Heart Attack

Clinical Trials on Glycogen Storage Disease Type II

Total 120 results

NCT03687333

Active, not recruiting

Evaluate Efficacy and Safety in Chinese Patients With Infantile-Onset Pompe Disease With One Year Alglucosidase Alfa Treatment

Conditions: Glycogen Storage Disease Type II
NCT03564561

Recruiting

Natural History of Pompe Disease

Conditions: Glycogen Storage Disease Type II, Adult
NCT02801539

Completed

Respiratory Muscle Training in L-Onset Pompe Disease (LOPD)

Conditions: Glycogen Storage Disease Type II
NCT01656590

Withdrawn

High Protein and Exercise Therapy Plus Nocturnal Enteral Feeding in Juvenile-onset Pompe Disease

Conditions: Glycogen Storage Disease Type II
NCT02782741

Active, not recruiting

Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies Avalglucosidase Alfa and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have Not Been Previously Treated for Pompe Disease

Conditions: Glycogen Storage Disease Type II;Pompe's Disease
NCT00763932

Completed

Extension Study of Long-term Safety and Efficacy of Myozyme in Patients With Pompe Disease Who Were Previously Enrolled in Genzyme Sponsored Enzyme Replacement Therapy (ERT) Studies

Conditions: Pompe Disease Infantile-Onset; Glycogen Storage Disease Type II
NCT00125879

Completed

Extension Study of Patients With Infantile-Onset Pompe Disease Who Were Previously Enrolled in Protocol AGLU01602

Conditions: Glycogen Storage Disease Type II
NCT00077662

Completed

A Prospective, Observational Study in Patients With Late-Onset Pompe Disease

Conditions: Glycogen Storage Disease Type II
NCT00765414

Completed

Extension Study of Long-term Safety and Efficacy of Myozyme for a Single Patient With Pompe Disease Who Were Previously Enrolled in Genzyme Sponsored ERT Studies.

Conditions: Pompe Disease Late-Onset; Glycogen Storage Disease Type II GSD II
NCT00059280

Completed

A Study of the Safety and Efficacy of rhGAA in Patients With Infantile-onset Pompe Disease

Conditions: Glycogen Storage Disease Type II
NCT02761421

Unknown status

Effect of Motor Development, Motor Function and Electrophysiologic Findings of IOPD Under ERT

Conditions: Glycogen Storage Disease Type II
NCT02032524

Active, not recruiting

Avalglucosidase Alfa Extension Study

Conditions: Glycogen Storage Disease Type II Pompe Disease
NCT03019406

Active, not recruiting

A Study to Assess Safety and Efficacy of Avalglucosidase Alfa Administered Every Other Week in Pediatric Patients With Infantile-onset Pompe Disease Previously Treated With Alglucosidase Alfa

Conditions: Glycogen Storage Disease Type II-Pompe's Disease
NCT00231400

Recruiting

Pompe Disease Registry Protocol

Conditions: Glycogen Storage Disease Type II; Pompe Disease
NCT00051935

Completed

A Study of the Safety and Pharmacokinetics of rhGAA in Siblings With Glycogen Storage Disease Type II

Conditions: Glycogen Storage Disease Type II; Pompe Disease; Acid Maltase Deficiency Disease; Glycogenosis 2
NCT00074932

Completed

Expanded Access Use of Myozyme (Alglucosidase Alfa) in Patients With Late-onset Pompe Disease

Conditions: Glycogen Storage Disease Type II; Glycogenosis 2
NCT00074919

Approved for marketing

Expanded Access Use of Myozyme (Alglucosidase Alfa) in Patients With Infantile-onset Pompe Disease

Conditions: Glycogen Storage Disease Type II; Glycogenosis 2
NCT00701129

Completed

An Exploratory Study of the Safety and Efficacy of Prophylactic Immunomodulatory Treatment in Myozyme-naive Cross-Reacting Immunologic Material (CRIM[-]) Patients With Infantile-Onset Pompe Disease

Conditions: Pompe Disease; Glycogen Storage Disease Type II
NCT00515398

Completed

A Study to Evaluate the Effects of Pharmacological Chaperones in Cells From Patients With Pompe Disease

Conditions: Pompe Disease; Glycogen Storage Disease Type II
NCT01410890

Completed

Pharmacokinetics of Alglucosidase Alfa in Patients With Pompe Disease

Conditions: Pompe Disease (Late-Onset); Glycogen Storage Disease Type II (GSD II)
NCT01898364

Completed

Safety and Efficacy Evaluation of Repeat neoGAA Dosing in Late Onset Pompe Disease Patients.

Conditions: Pompe Disease; Glycogen Storage Disease Type II (GSD II); Acid Maltase Deficiency
NCT01288027

Completed

Exploratory Muscle Biopsy Assessment Study in Patients With Late-Onset Pompe Disease Treated With Alglucosidase Alfa

Conditions: Pompe Disease (Late-Onset); Glycogen Storage Disease Type II (GSD II); Glycogenesis 2 Acid Maltase Deficiency
NCT04094948

Not yet recruiting

Phase II Clinical Trial of Clenbuterol in Adult Patients With Pompe Disease

Conditions: Pompe Disease (Late-onset)
NCT01758354

Completed

Newborn Screening Assay of Pompe's Disease

Conditions: Pompe Disease
NCT02898753

Terminated

VAL-1221 Delivered Intravenously in Ambulatory and Ventilator-free Participants With Late-Onset Pompe Disease

Conditions: Pompe Disease